Merck & Company (MRK) 50.95 $MRK
Shares of MRK Down 12.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 07, 9:41AM CDT
SmarTrend identified a Downtrend for Merck (NYSE:MRK) on August 21st, 2015 at $56.70. In approximately 2 months, Merck has returned 12.11% as of today's recent price of $49.83.
MRK: 50.95 (+1.15)
CareSync Secures $18 Million in Series B Funding
Business Wire - Wed Oct 07, 8:15AM CDT
CareSync, the leading provider of software and services for chronic disease management, today announced it has secured $18 million in Series B funding. Round participants include the Merck Global Health Innovation Fund (Merck GHI), Greycroft Partners and Harbert Venture Partners, as well as existing investors Tullis Health Investors, Clearwell Group, CDH Solutions and Travis Bond. The funding will help CareSync expand to meet demand for its services-enabled technology platform, strengthening its leading position in the emerging patient-centered care coordination market.
MRK: 50.95 (+1.15)
Research and Markets: Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
Business Wire - Wed Oct 07, 7:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f6r52/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering.
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67)
Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
M2 - Wed Oct 07, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqs29p/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering. The global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019. The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells. According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market. Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period. Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Oral - Parenteral Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Small Molecules - Biologics Key Vendors - Arbor Pharmaceuticals - Bristol-Myers Squibb - Eisai - F. Hoffmann-La Roche - Merck For more information visit http://www.researchandmarkets.com/research/tqs29p/global
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67)
Global Hospital Acquired Pneumonia (HAP) Pipeline Review, H2 2015 - 15 Companies & 22 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2hplb/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aridis Pharmaceuticals LLC - AstraZeneca Plc - Cardeas Pharma Corp. - Dong-A Socio Group - MedImmune, LLC - Meiji Seika Pharma Co., Ltd. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Motif Bio Plc - Nabriva Therapeutics AG - Savara Inc. - Serendex Pharmaceuticals A/S - Tetraphase Pharmaceuticals Inc. Drug Profiles - (amikacin fosfomycin) - (ceftazidime avibactam sodium) - (ceftolozane sulfate tazobactam sodium) - AA-139 - arbekacin - delafloxacin - eravacycline - iclaprim mesylate - lefamulin - MEDI-3902 - MEDI-4893 - molgramostim - Nu-2 - Panaecin - plazomicin sulfate - pseudomonas VAP vaccine - Pseudomonas aeruginosa vaccine - Qn-2251 - relebactam - tedizolid phosphate - tosatoxumab - vancomycin hydrochloride For more information visit http://www.researchandmarkets.com/research/z2...l_acquired
TTPH: 9.29 (+0.96), MRK: 50.95 (+1.15), AZN: 31.92 (-0.16), AKAO: 6.19 (+0.38), NBRV: 10.27 (unch)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 64.57 (+1.60), GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), INCY: 108.65 (-3.81), JUNO: 48.74 (+1.42), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), CELGZ: 1.75 (+0.08)
Global Chemotherapy Induced Nausea and Vomiting Pipeline Review, H2 2015 - 13 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk65k/chemotherapy) has announced the addition of the "Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acacia Pharma Limited - Aphios Corporation - Astellas Pharma Inc. - Helsinn Healthcare S.A. - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Co., Inc. - RedHill Biopharma Ltd. - SoluBest Ltd. - Suda Ltd - Teikoku Pharma USA, Inc. - Tesaro, Inc. Drug Profiles - (netupitant palonosetron hydrochloride) - APD-403 - aprepitant - dronabinol - FK-886 - granisetron ER - granisetron hydrochloride ER - netupitant - ondansetron hydrochloride - ondansetron hydrochloride CR - rolapitant hydrochloride - TPW-146 For more information visit http://www.researchandmarkets.com/research/kk...emotherapy
INSY: 26.20 (+0.44), TSRO: 41.75 (+1.40), RDHL: 12.60 (+0.24), HRTX: 26.07 (+2.30), MRK: 50.95 (+1.15)
Global and USA Biosimilar Market: Latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim...
PRWeb - Wed Oct 07, 1:01AM CDT
The global biosimilar and biobetter market is presenting lucrative opportunities to drug developers and manufacturers. Companies are no longer just looking at regional market, but must align global strategy for commercialization. This is easier said than done, especially with significant regulations and licensing differences.
MRK: 50.95 (+1.15)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Advaxis Cancer Immunotherapy on Hold Due to Patient Death
at The Street - Tue Oct 06, 4:07PM CDT
The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death.
ADXS: 10.51 (+0.20), MRK: 50.95 (+1.15), AZN: 31.92 (-0.16)
Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?
Brian Feroldi, The Motley Fool - Motley Fool - Tue Oct 06, 12:17PM CDT
Photo by CDC Global via Flickr Creative Commons. Biotech behemoth Regeneron Pharmaceuticals has been on a roll recently, thanks in large part to Eylea, the company's blockbuster wet age-related macular degeneration and macular edema drug....
JNJ: 94.98 (+1.56), INO: 6.02 (+0.20), NVAX: 7.26 (+0.46), MRK: 50.95 (+1.15), NLNK: 35.77 (+2.19), GSK: 39.72 (-0.05), REGN: 485.76 (+25.94)
VMTurbo Announces 21st Record Quarter, Record New Bookings
Marketwired - Tue Oct 06, 10:32AM CDT
VMTurbo, the only application performance control system for the software-defined data center, today announced its 21st consecutive record quarter, achieving 100% year-over-year growth in Q3 of 2015. With strong repeat business and a record number of new bookings, VMTurbo added companies such as PNC, Merck, the NCAA, PwC, and Cathay Bank to its family of over 1,200 customers.
MRK: 50.95 (+1.15)
Survey: Nearly One in Four Americans Admit to Being Misled by Health Information from Unverified Sources
PR Newswire - Tue Oct 06, 7:06AM CDT
Merck Manuals (called MSD Manuals outside of the United States and Canada), one of the world's most widely-used medical resources since 1899, today released the results of a survey revealing nearly 1 in 4 Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among millennials (adults age 18-34).
MRK: 50.95 (+1.15)
NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Business Wire - Tue Oct 06, 7:00AM CDT
NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Stephen Farrand, Ph. D., as senior vice president of global manufacturing.
NK: 13.45 (+1.90), MRK: 50.95 (+1.15)
Results from Merck's Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Business Wire - Mon Oct 05, 6:01PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 3(1) clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naive and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg)(2) and grazoprevir (100mg)(3) in patients with advanced CKD were published online in the medical journal The Lancet. Data from this study were initially presented at The International Liver Congress(TM)2015 in April 2015; additional information about that presentation and the design of the study can be found on the Merck newsroom.
MRK: 50.95 (+1.15)
Results from MSD's Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Business Wire - Mon Oct 05, 6:01PM CDT
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 3(1) clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naive and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg)(2) and grazoprevir (100mg)(3) in patients with advanced CKD were published online in the medical journal The Lancet. Data from this study were initially presented at The International Liver Congress(TM)2015 in April 2015; additional information about that presentation and the design of the study can be found in the MSD news release of 24 April 2015.
MRK: 50.95 (+1.15)
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
Business Wire - Mon Oct 05, 4:15PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck's development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria.
MRK: 50.95 (+1.15)
Merck (MRK) Breaks Through Resistance at $50.74
Comtex SmarTrend(R) - Mon Oct 05, 1:14PM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $49.55 today and has reached the first level of resistance at $50.74. Should the shares continue to rise, the resistance pivots of $51.35 and $53.15 will be of interest.
MRK: 50.95 (+1.15)
Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 10:40AM CDT
Merck (MRK) announced that its anti-programmed death receptor-1 therapy, Keytruda, has been approved by the FDA for the treatment of metastatic non-small cell lung cancer.
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67), ANIK: 32.27 (+0.60), REGN: 485.76 (+25.94)
Shares of MRK Down 12.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 07, 9:41AM CDT
SmarTrend identified a Downtrend for Merck (NYSE:MRK) on August 21st, 2015 at $56.70. In approximately 2 months, Merck has returned 12.11% as of today's recent price of $49.83.
MRK: 50.95 (+1.15)
CareSync Secures $18 Million in Series B Funding
Business Wire - Wed Oct 07, 8:15AM CDT
CareSync, the leading provider of software and services for chronic disease management, today announced it has secured $18 million in Series B funding. Round participants include the Merck Global Health Innovation Fund (Merck GHI), Greycroft Partners and Harbert Venture Partners, as well as existing investors Tullis Health Investors, Clearwell Group, CDH Solutions and Travis Bond. The funding will help CareSync expand to meet demand for its services-enabled technology platform, strengthening its leading position in the emerging patient-centered care coordination market.
MRK: 50.95 (+1.15)
Research and Markets: Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
Business Wire - Wed Oct 07, 7:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f6r52/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering.
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67)
Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
M2 - Wed Oct 07, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqs29p/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering. The global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019. The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells. According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market. Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period. Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Oral - Parenteral Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Small Molecules - Biologics Key Vendors - Arbor Pharmaceuticals - Bristol-Myers Squibb - Eisai - F. Hoffmann-La Roche - Merck For more information visit http://www.researchandmarkets.com/research/tqs29p/global
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67)
Global Hospital Acquired Pneumonia (HAP) Pipeline Review, H2 2015 - 15 Companies & 22 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2hplb/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aridis Pharmaceuticals LLC - AstraZeneca Plc - Cardeas Pharma Corp. - Dong-A Socio Group - MedImmune, LLC - Meiji Seika Pharma Co., Ltd. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Motif Bio Plc - Nabriva Therapeutics AG - Savara Inc. - Serendex Pharmaceuticals A/S - Tetraphase Pharmaceuticals Inc. Drug Profiles - (amikacin fosfomycin) - (ceftazidime avibactam sodium) - (ceftolozane sulfate tazobactam sodium) - AA-139 - arbekacin - delafloxacin - eravacycline - iclaprim mesylate - lefamulin - MEDI-3902 - MEDI-4893 - molgramostim - Nu-2 - Panaecin - plazomicin sulfate - pseudomonas VAP vaccine - Pseudomonas aeruginosa vaccine - Qn-2251 - relebactam - tedizolid phosphate - tosatoxumab - vancomycin hydrochloride For more information visit http://www.researchandmarkets.com/research/z2...l_acquired
TTPH: 9.29 (+0.96), MRK: 50.95 (+1.15), AZN: 31.92 (-0.16), AKAO: 6.19 (+0.38), NBRV: 10.27 (unch)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 64.57 (+1.60), GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), INCY: 108.65 (-3.81), JUNO: 48.74 (+1.42), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), CELGZ: 1.75 (+0.08)
Global Chemotherapy Induced Nausea and Vomiting Pipeline Review, H2 2015 - 13 Companies & 12 Drug Profiles
M2 - Wed Oct 07, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk65k/chemotherapy) has announced the addition of the "Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acacia Pharma Limited - Aphios Corporation - Astellas Pharma Inc. - Helsinn Healthcare S.A. - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Co., Inc. - RedHill Biopharma Ltd. - SoluBest Ltd. - Suda Ltd - Teikoku Pharma USA, Inc. - Tesaro, Inc. Drug Profiles - (netupitant palonosetron hydrochloride) - APD-403 - aprepitant - dronabinol - FK-886 - granisetron ER - granisetron hydrochloride ER - netupitant - ondansetron hydrochloride - ondansetron hydrochloride CR - rolapitant hydrochloride - TPW-146 For more information visit http://www.researchandmarkets.com/research/kk...emotherapy
INSY: 26.20 (+0.44), TSRO: 41.75 (+1.40), RDHL: 12.60 (+0.24), HRTX: 26.07 (+2.30), MRK: 50.95 (+1.15)
Global and USA Biosimilar Market: Latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim...
PRWeb - Wed Oct 07, 1:01AM CDT
The global biosimilar and biobetter market is presenting lucrative opportunities to drug developers and manufacturers. Companies are no longer just looking at regional market, but must align global strategy for commercialization. This is easier said than done, especially with significant regulations and licensing differences.
MRK: 50.95 (+1.15)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Advaxis Cancer Immunotherapy on Hold Due to Patient Death
at The Street - Tue Oct 06, 4:07PM CDT
The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death.
ADXS: 10.51 (+0.20), MRK: 50.95 (+1.15), AZN: 31.92 (-0.16)
Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?
Brian Feroldi, The Motley Fool - Motley Fool - Tue Oct 06, 12:17PM CDT
Photo by CDC Global via Flickr Creative Commons. Biotech behemoth Regeneron Pharmaceuticals has been on a roll recently, thanks in large part to Eylea, the company's blockbuster wet age-related macular degeneration and macular edema drug....
JNJ: 94.98 (+1.56), INO: 6.02 (+0.20), NVAX: 7.26 (+0.46), MRK: 50.95 (+1.15), NLNK: 35.77 (+2.19), GSK: 39.72 (-0.05), REGN: 485.76 (+25.94)
VMTurbo Announces 21st Record Quarter, Record New Bookings
Marketwired - Tue Oct 06, 10:32AM CDT
VMTurbo, the only application performance control system for the software-defined data center, today announced its 21st consecutive record quarter, achieving 100% year-over-year growth in Q3 of 2015. With strong repeat business and a record number of new bookings, VMTurbo added companies such as PNC, Merck, the NCAA, PwC, and Cathay Bank to its family of over 1,200 customers.
MRK: 50.95 (+1.15)
Survey: Nearly One in Four Americans Admit to Being Misled by Health Information from Unverified Sources
PR Newswire - Tue Oct 06, 7:06AM CDT
Merck Manuals (called MSD Manuals outside of the United States and Canada), one of the world's most widely-used medical resources since 1899, today released the results of a survey revealing nearly 1 in 4 Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among millennials (adults age 18-34).
MRK: 50.95 (+1.15)
NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Business Wire - Tue Oct 06, 7:00AM CDT
NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Stephen Farrand, Ph. D., as senior vice president of global manufacturing.
NK: 13.45 (+1.90), MRK: 50.95 (+1.15)
Results from Merck's Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Business Wire - Mon Oct 05, 6:01PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 3(1) clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naive and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg)(2) and grazoprevir (100mg)(3) in patients with advanced CKD were published online in the medical journal The Lancet. Data from this study were initially presented at The International Liver Congress(TM)2015 in April 2015; additional information about that presentation and the design of the study can be found on the Merck newsroom.
MRK: 50.95 (+1.15)
Results from MSD's Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Business Wire - Mon Oct 05, 6:01PM CDT
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 3(1) clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naive and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg)(2) and grazoprevir (100mg)(3) in patients with advanced CKD were published online in the medical journal The Lancet. Data from this study were initially presented at The International Liver Congress(TM)2015 in April 2015; additional information about that presentation and the design of the study can be found in the MSD news release of 24 April 2015.
MRK: 50.95 (+1.15)
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
Business Wire - Mon Oct 05, 4:15PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck's development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. They will share the prize with Youyou Tu for her discoveries concerning a novel therapy against malaria.
MRK: 50.95 (+1.15)
Merck (MRK) Breaks Through Resistance at $50.74
Comtex SmarTrend(R) - Mon Oct 05, 1:14PM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $49.55 today and has reached the first level of resistance at $50.74. Should the shares continue to rise, the resistance pivots of $51.35 and $53.15 will be of interest.
MRK: 50.95 (+1.15)
Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 10:40AM CDT
Merck (MRK) announced that its anti-programmed death receptor-1 therapy, Keytruda, has been approved by the FDA for the treatment of metastatic non-small cell lung cancer.
MRK: 50.95 (+1.15), BMY: 60.55 (+0.67), ANIK: 32.27 (+0.60), REGN: 485.76 (+25.94)
